A Real-world, Observational study to evaluate the clinical effectiveness and resource use patterns of Ranibizumab treat & extend regimen in patients with Neovascular Age-Related Macular Degeneration

Trial Profile

A Real-world, Observational study to evaluate the clinical effectiveness and resource use patterns of Ranibizumab treat & extend regimen in patients with Neovascular Age-Related Macular Degeneration

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms TERRA
  • Most Recent Events

    • 29 Jun 2017 New trial record
    • 01 Jun 2017 Results (n=145; data cut-off 15 Nov 2016) published in the Ophthalmology and Therapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top